AbbVie: 3 Key Takeaways for Long-Term Investors

Impact · against what's priced in

The news is largely confirmatory for AbbVie, as the market already assumes the success of Skyrizi and the growth of the neuroscience portfolio to offset Humira. The $5 billion peak revenue target for Parkinson's is a positive incremental detail, but overall the updates align with the growth rates the stock price already requires.

ABBV+0.10

Already priced in

The price assumes

SKYRIZI and RINVOQ replacing HUMIRA's lost revenue

Skyrizi capturing half of new IBD patients confirms the market's expectation that newer immunology drugs will successfully offset Humira's patent-expiry headwinds.

What ABBV's price assumes · Sep 4

• earnings▲13%
• cash flow▲9%
• guidance▲4%
• dividends
• healthcare
• pharmaceuticals
• ABBV